Role of hyperglycaemia in the pathogenesis of hypotension observed in type-1 diabetic rats

International Journal of Experimental Pathology

Volumn 89, Issue 4, 2008, Pages 292-300

  Liu, I Min ^b   Chang, Cheng Kuei ^c,d   Juang, Shiow Wen ^a   Kou, Dai Huang ^b   Tong, Yat Ching ^a   Cheng, Kai Chun ^a   Cheng, Juei Tang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAJEN UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiac M2 muscarinic receptor; Diabetic rats; Gene expression; Hyperglycaemia; Insulin; Phlorizin

Indexed keywords

ARECAIDINE PROPARGYL ESTER; INSULIN; MESSENGER RNA; MUSCARINIC M2 RECEPTOR; PHENYLEPHRINE; PHLORIZIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HEART RATE; HYPERGLYCEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT;

ANIMALS; ARECOLINE; BAROREFLEX; CELL LINE; CHOLINERGIC AGONISTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION; GLUCOSE; HYPERGLYCEMIA; HYPOTENSION; INSULIN; MALE; PHENYLEPHRINE; PHLORHIZIN; RATS; RATS, WISTAR; RECEPTOR, MUSCARINIC M2; RNA, MESSENGER;

EID: 47649123927     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2008.00595.x     Document Type: Article

References (34)

1. Boulton A.J., Vinik A.I., Arezzo J.C. et al. (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28, 956 962.
2. Bucking C. Wood C.M. (2005) Renal regulation of plasma glucose in the freshwater rainbow trout. J. Exp. Biol. 208, 2731 2739.
3. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.J. (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51, 1938 1948.
4. Cooper M.E. (2004) Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am. J. Hypertens. 17, 31S 38S.
5. Dall'Ago P., Silva V.O., De Angelis K.L., Irigoyen M.C., Fazan R. Jr., Salgado H.C. (2002) Reflex control of arterial pressure and heart rate in short-term streptozotocin diabetic rats. Braz. J. Med. Biol. Res. 35, 843 849.
6. Dall'ago P., D'Agord Schaan B., da Silva V.O. et al. (2007) Parasympathetic dysfunction is associated with baroreflex and chemoreflex impairment in streptozotocin-induced diabetes in rats. Auton. Neurosci. 131, 28 35.
7. De Angelis K., Schaan B.D., Maeda C.Y., Dall'Ago P., Wichi R.B., Irigoyen M.C. (2002) Cardiovascular control in experimental diabetes. Braz. J. Med. Biol. Res. 35, 1091 1100.
8. Dhein S., van Koppen C.J., Brodde O.E. (2001) Muscarinic receptors in the mammalian heart. Pharmacol. Res. 44, 161 182.
9. Eppens M.C., Craig M.E., Cusumano J. et al. (2006) Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 29, 1300 1306.
10. Frattola A., Parati G., Gamba P. et al. (1997) Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 40, 1470 1475.
11. Gando S., Hattori Y., Akaishi Y., Nishihira J., Kanno M. (1997) Impaired contractile response to beta adrenoceptor stimulation in diabetic rat hearts: alterations in beta adrenoceptors-G protein-adenylate cyclase system and phospholamban phosphorylation. J. Pharmacol. Exp. Ther. 282, 475 484.
12. Gazit H., Silman I., Dudai Y. (1979) Administration of an organophosphate causes a decrease in muscarinic receptor levels in rat brain. Brain Res. 174, 351 356.
13. Genuth S. (2006) Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr. Pract. 12, 34S 41S.
14. Harvey R.D. Belevych A.E. (2003) Muscarinic regulation of cardiac ion channels. Br. J. Pharmacol. 139, 1074 1084.
15. Heise T., Magnusson K., Heinemann L., Sawicki P.T. (1998) Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 32, 243 248.
16. Khamaisi M., Wexler I.D., Skrha J., Strojek K., Raz I., Milicevic Z. (2003) Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. Isr. Med. Assoc. J. 5, 801 806.
17. Laemmli U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680 685.
18. Liu I.M., Tzeng T.F., Tsai C.C., Lai T.Y., Chang C.T., Cheng J.T. (2003) Increase in adenosine A1 receptor gene expression in the liver of streptozotocin-induced diabetic rats. Diabetes Metab. Res. Rev. 19, 209 215.
19. Liu T.P., Juang S.W., Cheng J.T., Tong Y.C. (2005) The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats. Neurosci. Lett. 383, 131 135.
20. Maeda C.Y., Fernandes T.G., Timm H., Irigoyen M.C. (1995) Autonomic dysfunction in short-term experimental diabetes. Hypertension 26, 1000 1004.
21. Mentink C.J., Kilhovd B.K., Rondas-Colbers G.J., Torjesen P.A., Wolffenbuttel B.H. (2006) Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth. J. Med. 64, 10 16.
22. Mulé G., Nardi E., Cottone S. et al. (2007) Impact of the metabolic syndrome on total arterial compliance in essential hypertension patients. J. Cardiometab. Syndr. 2, 84 90.
23. Sanyal S.N., Arita M., Ono K. (2002) Inhomogeneous derangement of cardiac autonomic nerve control in diabetic rats. Circulation J. 66, 283 238.
24. Selwitz R.H. Pihlstrom B.L. (2003) How to lower risk of developing diabetes and its complications: recommendations for the patient. J. Am. Dent. Assoc. 134, 54S 58S.
25. Sheetz M.J. King G.L. (2002) Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288, 2579 2588.
26. Sobel B.E. Schneider D.J. (2005) Cardiovascular complications in diabetes mellitus. Curr. Opin. Pharmacol. 5, 143 148.
27. Takagawa Y., Berger M.E., Tuck M.L., Golub M.S. (2002) Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed rat. Hypertens. Res. 25, 197 202.
28. Thrasher T.N. (2005) Baroreceptors, baroreceptor unloading, and the long-term control of blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, 819R 827R.
29. Tong Y.C., Hung Y.C., Lin S.N., Cheng J.T. (1996) Alterations in urinary bladder synaptosomal neurotransmitter concentrations in two-week streptozotocin-induced diabetic rats. Neurosci. Lett. 206, 165 168.
30. Tong Y.C., Chin W.T., Cheng J.T. (1999) Alterations in M2-muscarinic receptor protein and mRNA in diabetic rat urinary bladders. Neurosci. Lett. 277, 173 176.
31. Tumiatti V., Wehrle J., Hildebrandt C. et al. (2000) Muscarinic properties of compounds related to arecaidine propargyl ester. Arzneimittelforschung 50, 11 15.
32. Wei M., Ong L., Smith M.T. et al. (2003) The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 12, 44 50.
33. Wise B.C., Shoji M., Kuo J.F. (1980) Decrease or increase in cardiac muscarinic cholinergic receptor number in rats treated with methacholine or atropine. Biochem. Biophys. Res. Commun. 92, 1136 1142.
34. + depolarization in cultured H9c2 myotubes. Am. J. Physiol. 277, 259E 267E.